X-ray phase-contrast imaging techniques have emerged as a powerful supplement to conventional absorption-based methods, allowing researchers and clinicians to visualise soft tissues and subtle ...
Study marks the first positive Phase 3 study for mezigdomide and the second positive Phase 3 study for the Bristol Myers Squibb CELMoD program PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb ...
VT-1953 treatment over 14 days resulted in highly statistically significant improvements in bad smell or malodor associated with malignant fungating wound (primary endpoint) (P = 0.002).
Results that may be inaccessible to you are currently showing.
Hide inaccessible results